2 June 2021 - Experts expect to see a second wave of biosimilar approvals, though continued Medicare Part D reimbursement challenges hobble uptake, according to presenters discussing the current landscape and future projections for the biosimilars market at the annual meeting of the Association for Accessible Medicines on 27 May.

“We have come a long way in the last two years,” said Craig Burton, vice-president of policy for Association for Accessible Medicines. Where you used to see one or two biosimilar products reference innovators in a single category, now we have multiple categories that have two or more biosimilar products, indicating to me that the market is healthy and there are opportunities for manufacturers to launch in the US.”

Janet Woodcock, acting commissioner of the US FDA, made the same observation at the meeting, noting a “significant increase” in biosimilars approvals as the pharmaceutical industry has shown renewed interest in developing these drugs.

Read Regulatory Affairs Professional Society article